Dr. Muchmore brings a strong combination of both private practice understanding and pharmaceutical industry experience focused on diabetes and osteoporosis. His over 20 years of drug development and regulatory affairs experience have been in both pharmaceutical and biotech organizations, Eli Lilly in Indianapolis, IN and Halozyme Therapeutics of San Diego, CA. He has authored over 50 peer-reviewed publications in biochemistry, diabetes, osteoporosis, and breast cancer. Dr. Muchmore has 13+ years in tertiary care Endocrinology and Metabolism medical practice and was also the Program director, Endocrinology and Metabolism training fellowship at Scripps Clinic and Research Foundation, La Jolla, CA. He also trained in Internal Medicine specialty and Endocrinology/Metabolism subspecialty training and laboratory research, University of Washington, Seattle, WA. Dr. Muchmore received medical training and laboratory research at the University of California, San Diego and an AB in Biology from Stanford University.
Click here to view consultant's profile
Officers
G. Alexander Fleming, MD
Executive Chairman
Thomas Seoh
President and Chief Executive Officer
Clinical Development
Regulatory Affairs
EU Regulatory
Clinical Operations/Project Management
Julie Waltz Gerlach, B.S.N., M.P.H., R.A.C.
Pre-Clinical
CMC, Formulation/Process Development & Sourcing
Medical Device
QA/QC
Julie Waltz Gerlach, B.S.N., M.P.H., R.A.C.
Medical Writing/Electronic Submissions
Process & Innovation Management
Elizabeth Whalley Buono, BSN, RN, MBA, JD
Defense & National Security Practice
Commercializing and Business & Corporate Strategy
Kinexum Associate
Founders